DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on advancing innovative therapies for neurological and kidney diseases. Headquartered in Minneapolis, Minnesota, the company is dedicated to addressing unmet medical needs through its proprietary drug development programs. DiaMedica's lead candidate, DM199, is designed to enhance renal function in patients with diabetic kidney disease, reflecting its commitment to pioneering treatment options that improve patient outcomes. With a strong pipeline and a strategic focus on clinical innovation, DiaMedica is positioned to make a significant impact in the biopharmaceutical landscape.